in Federally Assisted Programs of the Department of Agriculture—Effectuation of Title VI of the Civil Rights Act of 1964.

Certain OMB circulars also apply to USDA grant programs and must be followed by a grantee under this program. The policies, guidance, and requirements of the following, or their successors, may apply to the award, acceptance and use of assistance under this program and to the remedies for noncompliance, except when inconsistent with the provisions of the Agriculture, Rural Development and Related Agencies Appropriations Acts, other Federal statutes or the provisions of this NOFA:

- OMB Circular No. A–87 (Cost Principles Applicable to Grants, Contracts and Other Agreements with State and Local Governments);
- OMB Circular A–21 (Cost Principles for Education Institutions);
- OMB Circular No. A–122 (Cost Principles for Nonprofit Organizations);
- OMB Circular A–133 (Audits of States, Local Governments, and Non-Profit Organizations);
- 7 CFR part 3015 (Uniform Federal Assistance Regulations);
- 7 CFR part 3016 (Uniform Administrative Requirements for Grants and Cooperative Agreements to State, Local, and Federally recognized Indian tribal governments);
- 7 CFR part 3017 (Governmentwide debarment and suspension (non-procurement) and governmentwide requirements for drug-free workplace (grants));
- 7 CFR part 3018 (New restrictions on Lobbying);
- 7 CFR part 3019 (Uniform administrative requirements for grants and Agreements with Institutions of Higher Education, Hospitals, and other Non-Profit Organizations); and
- 7 CFR part 3052 (Audits of States, local governments, and non-profit organizations).

Compliance with additional OMB Circulars or government-wide regulations may be specified in the grant agreement.

3. Reporting

The grantee will be required to provide periodic financial and performance reports under USDA grant regulations and RUS rules and to submit a final project performance report. The nature and frequency of required reports are established in USDA grant regulations and the project-specific grant agreements.

VII. Agency Contact

The Agency Contact for this grant announcement is Karen Larsen, Management Analyst, U.S. Department of Agriculture, Rural Utilities Service, Electric Program, 1400 Independence Avenue, SW., STOP 1560, Room 5165 South Building, Washington, DC 20250–1560. Telephone 202–720–9545, Fax 202–690–0717, e-mail *Karen.Larsen@usda.gov*.

Dated: May 18, 2005.

Curtis M. Anderson,

Acting Administrator, Rural Utilities Service.

[FR Doc. 05–10378 Filed 5–24–05; 8:45 am]

BILLING CODE 3410–15–P

DEPARTMENT OF COMMERCE

Foreign–Trade Zones Board

[Docket 22–2005]

Foreign–Trade Zone 99 - Wilmington, Delaware, Expansion of Subzone and Manufacturing Authority Subzone 99D, AstraZeneca Pharmaceuticals LP (Pharmaceutical Products), Newark, Delaware

An application has been submitted to the Foreign–Trade Zones Board (the Board) by the Delaware Economic Development Office, grantee of FTZ 99, requesting to expand the subzone and the scope of manufacturing authority under zone procedures within Subzone 99D, at the AstraZeneca Pharmaceuticals LP (AstraZeneca) facility in Newark, Delaware. It was formally filed on May 17, 2005.

Subzone 99D was approved by the Board in 1994 at AstraZeneca's plant (2 bldgs. on 156 acres/520,700 sq. ft.) located at 587 Old Baltimore Pike, Newark, Delaware, some 10 miles west of Wilmington. The facility (530 employees) is used to produce and/or distribute a wide range of pharmaceuticals, with specific authority granted for the manufacture of several products under zone procedures (Board Order 717, 12/02/94).

Subzone 99D is currently requesting to expand the subzone at the existing facility (Site 1) to include additions to existing buildings (totaling 114,100 sq. ft.) and to include another site (Site 2) for the manufacture of clinical trial products. AstraZeneca is also requesting to include in its scope of authority general categories of inputs and final products that it may produce under zone procedures in the future.

Proposed Site 2 (30 buildings, 3,226,805 sq. ft. (526,552 mfg. sq. ft.) on 163 acres, which includes a potential expansion of 7 buildings totaling 1,154, 298 sq. ft. (318,548 mfg. sq. ft.)) is located at 1800 Concord Pike, Wilmington, Delaware, some 20 miles from Site 1. It will be used to produce finished dose pharmaceutical formulations of clinical trial products (HTSUS 3004.90, duty–free). Materials sourced from abroad represent 90 to 95 percent of all materials used in production proposed for zone procedures. Inverted tariff savings will initially result from the following bulk active ingredients, all subject to a 6.5% duty rate: AZD 0328 (HTSUS 2934.99.9000), AZD 5455 (HTSUS 2933.39.9100) and AZD 4522 (HTSUS 2935.00.6000). Finished dose products will be transferred to Site 1 for packaging and shipping.

The application also requests authority to include a broad range of inputs and pharmaceutical final products that it may produce under FTZ procedures in the future. (New major activity in these inputs/products could require review by the FTZ Board.) General HTSUS categories of inputs include: 1108, 1212, 1301, 1302, 1515, 1516, 1520, 1521, 1702, 1905, 2106, 2207, 2302, 2309, 2501, 2508, 2510, 2519, 2520, 2526, 2710, 2712, 2807, 2809, 2811, 2814, 2815, 2816, 2817, 2821, 2823, 2825, 2826, 2827, 2829, 2831, 2832, 2833, 2835, 2836, 2837, 2839, 2840, 2841, 2842, 2843, 2844, 2846, 2851, 2901, 2902, 2903, 2904 (except for HTS 2904.20.5000), 2905, 2906, 2907, 2908, 2909, 2910, 2911, 2912, 2913, 2914, 2915, 2916, 2917, 2918, 2919, 2920, 2921, 2922, 2923, 2924, 2925, 2926, 2927, 2928, 2929, 2930, 2931, 2932, 2933, 2934, 2935, 2936, 2937, 2938, 2939, 2940, 2941, 2942, 3001, 3002, 3003, 3004, 3005, 3006, 3102, 3104, 3301, 3302, 3305, 3401, 3402, 3403, 3404, 3502, 3503, 3505, 3506, 3507, 3802, 3804, 3808, 3809, 3815, 3822, 3823, 3824, 3901, 3906, 3910, 3911, 3912, 3913, 3914, 3915, 3919, 3920, 3921, 3923, 4016, (4202.92.1000, 4202.92.9060, 4202.99.1000, 4202.99.5000 (plastic only)), 4817, 4819, 4901, 4902, 5403, 7010, 7607, 8004, 8104, 8309, 8481, 9018, and 9602. The duty rates on these products range from duty–free to 17%.

Final products that may be produced from the inputs listed above include these general HTSUS categories: 2302, 2309, 2902, 2903, 2904, 2905, 2906, 2907, 2909, 2910, 2912, 2913, 2914, 2915, 2916, 2917, 2918, 2920, 2921, 2922, 2923, 2924, 2925, 2926, 2928, 2930, 2931, 2932, 2933, 2934, 2935, 2936, 2937, 2938, 2939, 2941, 2942, 3001, 3002, 3003, 3004, 3006, 3802, 3804, 3808, 3809, 3824, 3910, 3911, 3912, 3913, and 3914. The duty rates on these products range from duty–free to 7.5%.

Zone procedures would exempt AstraZeneca from Customs duty

payments on foreign materials used in production for export. On domestic shipments, the company would be able to defer Customs duty payments on foreign materials, and to choose the duty rate that applies to finished products (duty–free) instead of the rates otherwise applicable to the foreign input materials (6.5%). The application indicates that the savings from zone procedures would help improve AstraZeneca's international competitiveness.

In accordance with the Board's regulations, a member of the FTZ staff has been designated examiner to investigate the application and report to the Board.

Public comment is invited from interested parties. Submissions (original and 3 copies) shall be addressed to the Board's Executive Secretary at one of the following addresses:

1. Submissions Via Express/Package Delivery Services: Foreign–Trade-Zones Board, U.S. Department of Commerce, Franklin Court Building - Suite 4100W, 1099 14th St. NW, Washington, D.C. 20005; or
2. Submissions Via the U.S. Postal Service: Foreign–Trade-Zones Board, U.S. Department of Commerce, FCB - Suite 4100W, 1401 Constitution Ave. NW, Washington, D.C. 20230.

The closing period for their receipt is July 25, 2005. Rebuttal comments in response to material submitted during the foregoing period may be submitted during the subsequent 15-day period (to August 8, 2005).

A copy of the application and accompanying exhibits will be available for public inspection at the Office of the Foreign–Trade Zones Board's Executive Secretary at address Number 1 listed above, and at the U.S. Department of Commerce Export Assistance Center, The Curtis Center - Suite 580, West 601 Walnut Street - Independence Square West, Philadelphia, PA 19106–3304.

Dated: May 19, 2005.

Dennis Puccinelli,

Executive Secretary.

[FR Doc. 05–10461 Filed 5–24–05; 8:45 am]

BILLING CODE 3510–DS–S

DEPARTMENT OF COMMERCE

Foreign–Trade Zones Board

[Docket 23–2005]

Foreign–Trade Zone 7 Mayaguez, Puerto Rico, Application for Subzone, Abbott Laboratories (Pharmaceutical Products), Barceloneta, Puerto Rico

An application has been submitted to the Foreign–Trade Zones (FTZ) Board (the Board) by the Puerto Rico Industrial Development Corporation, grantee of FTZ 7, requesting special–purpose subzone status for the pharmaceutical manufacturing facilities of Abbott Pharmaceuticals PR LTD. (APPR), Abbott Health Products, Inc. (AHP), and Abbott Biotechnology LTD (ABL), subsidiaries of Abbott Laboratories (Abbott), located in Barceloneta, Puerto Rico. The application was submitted pursuant to the Foreign–Trade Zones Act, as amended (19 U.S.C. 81a–81u), and the regulations of the Board (15 CFR part 400). It was formally filed on May 17, 2005.

The proposed subzone (123 buildings of 2,151,957 square feet (approx. 90% mfg. sq. ft.) on 276 acres, with a possible expansion of 34 buildings of 2,330,579 sq. ft.) is comprised of one site located at Road No. 2, Km 58.0, Barceloneta, Puerto Rico. The Abbott facility (2,200 employees) manufactures, tests, packages, and warehouses pharmaceutical and diagnostic products, activities which it is proposing to perform under zone procedures.

It will be used to produce finished dose pharmaceutical formulations and diagnostic products. Initially, the company is proposing to produce the antibiotics, clarythromycin and erythromycin; and Depakote®, a treatment for epilepsy, migraine and bipolar disorder, under zone procedures. Materials sourced from abroad represent 5–10 percent of the value of the finished products manufactured under the proposed primary scope. Inverted tariff savings will initially result from the following ingredients: Beta Carb (HTSUS 2917.19.7050), hexamethyldisilozane (HTSUS 2931.00.9010), and hypromellose phtalate (HTSUS 3912.90.0090). Some 60 to 80 percent of the proposed production under zone procedures will be exported.

The application also requests authority to include a broad range of inputs and pharmaceutical final products that it may produce under FTZ procedures in the future. (New major activity in these inputs/products could require review by the FTZ Board.) General HTSUS categories of inputs include: 1108, 1212, 1301, 1302, 1515, 1516, 1520, 1521, 1702, 1905, 2106, 2207, 2302, 2309, 2501, 2508, 2510, 2519, 2520, 2526, 2710, 2712, 2807, 2809, 2811, 2814, 2815, 2816, 2817, 2821, 2823, 2825, 2826, 2827, 2829, 2831, 2832, 2833, 2835, 2836, 2837, 2839, 2840, 2841, 2842, 2844, 2846, 2851, 2901, 2902, 2903, 2904 (except for 2904.20.5000), 2905, 2906, 2907, 2908, 2909, 2910, 2911, 2912, 2913, 2914, 2915, 2916, 2917, 2918, 2919, 2920, 2921, 2922, 2923, 2924, 2925, 2926, 2927, 2928, 2929, 2930, 2931, 2932, 2933, 2934, 2935, 2936, 2937, 2938, 2939, 2940, 2941, 2942, 3001, 3002, 3003, 3004, 3005, 3006, 3102, 3104, 3301, 3302, 3305, 3401, 3402, 3403, 3404, 3502, 3503, 3505, 3506, 3507, 3802, 3804, 3808, 3809, 3815, 3822, 3823, 3824, 3906, 3910, 3911, 3912, 3913, 3914, 3915, 3919, 3920, 3921, 3923, 4016, (4202.92.1000, 4202.92.9060, 4202.99.1000, 4202.99.5000 (plastic only)), 4817, 4819, 4901, 4902, 7010, 7607, 8004, 8104, 8309, 8481, 9018, 9602. Duty rates for these materials range from duty–free to 17%.

Final products that may be produced from the inputs listed above include these general HTSUS categories: 2302, 2309, 2825, 2902, 2903, 2904, 2905, 2906, 2907, 2909, 2910, 2912, 2913, 2914, 2915, 2916, 2917, 2918, 2920, 2921, 2922, 2924, 2925, 2926, 2928, 2930, 2931, 2932, 2933, 2934, 2935, 2936, 2937, 2938, 2939, 2940, 2941, 2942, 3001, 3002, 3003, 3004, 3006, 3503, 3507, 3802, 3804, 3808, 3809, 3824, 3910, 3911, 3912, 3913, 3914 and 9018. Duty rates for these products range from duty–free to 7.5%.

Zone procedures would exempt Abbott from Customs duty payments on foreign materials used in production for export (some 60–80% of shipments). On domestic shipments, the company would be able to defer Customs duty payments on foreign materials, and to choose the duty rate that applies to finished products (duty–free) instead of the rates otherwise applicable to the foreign input materials (3.7% - 5.2%). The application indicates that the savings from zone procedures would help improve Abbott's international competitiveness.

In accordance with the Board's regulations, a member of the FTZ staff has been designated examiner to investigate the application and report to the Board.

Public comment is invited from interested parties. Submissions (original and 3 copies) shall be addressed to the Board's Executive Secretary at one of the following addresses: